MS specialists, neurologists, neurology APPs and neurology nurses, fellows, residents, nurse practitioners, physicians’ assistants, physical therapists, nurses, and pharmacists who comprise the MS care team, as well as other healthcare professionals involved in the management of patients with multiple sclerosis.
Analyze treatments recently completed or still in phase III clinical trials
Review other emerging treatments in the multiple sclerosis therapeutic landscape
Evaluate current data on CAR-T cell therapeutics
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Mark S. Freedman, MD
|
Consultant/Advisor: Actelion Pharmaceuticals; Alexion Pharmaceuticals; Amgen; AstraZeneca; EMD Serono; Genentech, Inc.; Horizon Therapeutics; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche AG; Sanofi
Grant/Research Support: Sanofi Speaker’s Bureau: Novartis Pharmaceuticals Corporation; Roche AG |
Timothy Hayes, MD, PhD and Kim Cheramie, PhD, MSN, RN, NPDA-BC hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of Continuing Pharmacy Education Credit (UAN JA4008190-0000-26-026-H01-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Genentech, Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
